Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Venture Life ( (GB:VLG) ).
Venture Life Group PLC reported strong financial results for 2024, with an 18.9% increase in group revenue and a significant improvement in gross profit margins. The company has entered into a binding agreement to sell its contract development and manufacturing operations and certain non-core products for €62 million, which is expected to simplify its business and provide cash for growth investments. The divestment aligns with the company’s strategic focus on high-margin consumer healthcare brands, positioning it for future growth in the proactive healthy longevity market.
More about Venture Life
Venture Life is an international consumer self-care company focused on commercializing products for the global self-care market. Headquartered in the UK, the Group’s product portfolio includes Balance Activ in women’s intimate healthcare, Earol® for ENT care, Lift and Glucogel for energy and glucose management, and the Health & Her range supporting the hormonal lifecycle. These products are available through health & beauty stores, pharmacies, grocery multiples, and e-commerce channels globally.
Average Trading Volume: 340,134
Technical Sentiment Signal: Buy
Current Market Cap: £64.35M
For a thorough assessment of VLG stock, go to TipRanks’ Stock Analysis page.